BioTie (Finland) and Roche collaboration targets inflammatory disease.

Roche and BioTie have announced a collaboration and option agreement to develop BioTie’s proprietary small molecule vascular adhesion protein-1 (VAP-1) program targeting inflammatory diseases. Inhibiting VAP-1 is believed to reduce inflammation by regulating the flow of leukocytes, or white blood cells, to inflamed tissues.BioTie’s proprietary drug development target, Vascular Adhesion Protein-1 (VAP-1), is a dual-function molecule with enzymatic and adhesion activities.

Under the terms of the agreement, Roche will contribute its expertise to BioTie’s development of VAP-1 small molecule inhibitor candidates. Headquartered in Basel, Switzerland, Roche is one of the world’s leading research-intensive healthcare groups.

BioTie Therapies is a Finnish biotech company specialized in pharmaceutical product development. Its main focus is on products for the treatment of dependence disorders, inflammatory diseases and thrombosis.
For more information, please visit www.biotie.com.

News Source: Eeva Järvinen, ScanBalt webeditor in Finland.